Oppenheimer analyst Leland Gershell reiterated a Perform rating on Corbus Pharmaceuticals (NASDAQ: CRBP) but noted that the upcoming Lupus data ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE